Molecular Formula | C18H17N3O4S |
Molar Mass | 371.41 |
Density | 1.427 |
Melting Point | 162 °C(dec.) |
Boling Point | 551.0±60.0 °C(Predicted) |
pKa | 7.86±0.40(Predicted) |
Storage Condition | under inert gas (nitrogen or Argon) at 2–8 °C |
In vitro study | In vitro, The IC50 was 0.6-2.6 μm for neuroblastoma at ABT-751 and 0.7-4.6 μm for other solid tumor cell lines, with selective toxicity. Moreover, ABT-751 also acts selectively on dynamic microtubules, which can be used to explain the continuous acetylation of α-microtubule positive polymeric tubules at the concentration of ABT-751 ic90. |
In vivo study | In ABT-751, the Calu-6 transplanted tumor model was treated with 100 and 75 mg/kg per day, which had significant anticancer activity. When combined with Cisplatin, ABT-751 further delayed tumor growth, which was dose dependent. ABT-751 alone in HT-29 colon transplantation tumor model, also has significant anticancer activity, when combined with 5-FU, further delay tumor growth, this effect also exists dose dependent. ABT-751 in dogs with lymphoma, with dose-limiting toxicity, with anorexia Vomit, Diarrhea, with a maximum tolerated dose (MTD) of 350 mg/m(2) PO q24h. Furthermore, the mean AUC and CMAX were 350 μg-hour/mL and 5.55 μg/mL, respectively, at the maximum tolerated dose (MTD) of 0.9 mg/m(2) PO q24h ABT-751. |
RTECS | DB2734000 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.692 ml | 13.462 ml | 26.924 ml |
5 mM | 0.538 ml | 2.692 ml | 5.385 ml |
10 mM | 0.269 ml | 1.346 ml | 2.692 ml |
5 mM | 0.054 ml | 0.269 ml | 0.538 ml |